212 related articles for article (PubMed ID: 24418940)
1. The in-vitro anticoagulant effect of rivaroxaban in neonates.
Attard C; Monagle P; Kubitza D; Ignjatovic V
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):237-40. PubMed ID: 24418940
[TBL] [Abstract][Full Text] [Related]
2. The in vitro anticoagulant effect of rivaroxaban in children.
Attard C; Monagle P; Kubitza D; Ignjatovic V
Thromb Res; 2012 Nov; 130(5):804-7. PubMed ID: 22884545
[TBL] [Abstract][Full Text] [Related]
3. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
6. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
7. Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.
Novak M; Schlagenhauf A; Bernhard H; Schweintzger S; Leschnik B; Muntean W
Blood Coagul Fibrinolysis; 2011 Oct; 22(7):588-92. PubMed ID: 21799400
[TBL] [Abstract][Full Text] [Related]
8. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
Molenaar PJ; Dinkelaar J; Leyte A
Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
[TBL] [Abstract][Full Text] [Related]
9. Determination of rivaroxaban in human plasma samples.
Harenberg J; Erdle S; Marx S; Krämer R
Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
[TBL] [Abstract][Full Text] [Related]
10. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
Samama MM
Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
[TBL] [Abstract][Full Text] [Related]
12. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
14. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
Harenberg J; Marx S; Krämer R; Giese C; Weiss C
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):637-41. PubMed ID: 21986465
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
Kreutz R
Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
Mani H; Hesse C; Stratmann G; Lindhoff-Last E
Thromb Haemost; 2011 Jul; 106(1):156-64. PubMed ID: 21655672
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
Douxfils J; Mullier F; Loosen C; Chatelain C; Chatelain B; Dogné JM
Thromb Res; 2012 Dec; 130(6):956-66. PubMed ID: 23006523
[TBL] [Abstract][Full Text] [Related]
18. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
19. Assays for measuring rivaroxaban: their suitability and limitations.
Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
[TBL] [Abstract][Full Text] [Related]
20. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
Harenberg J; Marx S; Weiss C; Krämer R; Samama M; Schulman S;
J Thromb Haemost; 2012 Jul; 10(7):1433-6. PubMed ID: 22947062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
